

Amanda Harris Corbett, PharmD, BCPS, FCCP

OFFICE: Eshelman School of Pharmacy
CB# 7569, 3202 Kerr Hall
The University of North Carolina
Chapel Hill, North Carolina
27599-7569
(919) 843-2280

PROFESSIONAL EXPERIENCE

August 2018-present **Assistant Dean, Professional Curriculum**
University of North Carolina at Chapel Hill
Eshelman School of Pharmacy
Chapel Hill, North Carolina

January 2017-present **Associate Director of Global Engagement**
University of North Carolina at Chapel Hill
Eshelman School of Pharmacy
Chapel Hill, North Carolina

August 2016-present **Founder and Chief Executive Officer**
World of One Global Integrative Health, LLC
Carrboro, North Carolina

June 2013-present **Global Pharmacology Coordinator**
Institute for Global Health and Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Dec 2011-present **Clinical Associate Professor**
University of North Carolina at Chapel Hill
Eshelman School of Pharmacy
School of Medicine
Chapel Hill, North Carolina

Aug 2012-Feb 2013 **Clinical Pharmacist**
Chapel Hill Integrative Medicine Center
Chapel Hill, North Carolina

Sept 2011-present **General Supervisor**
College of Pathology Accredited
Antiretroviral Therapeutic Drug Monitoring Service
UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina

July 2003-July 2016 **Clinical Specialty Pharmacist**
UNC Infectious Diseases Clinic
Chapel Hill, North Carolina

October 2007 – Dec 2011

Clinical Assistant Professor

University of North Carolina at Chapel Hill
School of Medicine
Chapel Hill, North Carolina

July 2003 – Nov 2011

Clinical Assistant Professor

University of North Carolina at Chapel Hill
Eshelman School of Pharmacy
Chapel Hill, North Carolina

January 2005 - present

Clinical Associate

Center for AIDS Research
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

January 2004 - December 2006

Co-investigator

Adult AIDS Clinical Trials Group
Pharmacology Support Laboratory
University of North Carolina at Chapel Hill
School of Pharmacy
Chapel Hill, North Carolina

July 2000 - June 2003

Clinical Instructor

University of North Carolina at Chapel Hill
School of Pharmacy
Chapel Hill, North Carolina

EDUCATION AND TRAINING

August 2016-Present

Integrative Medicine Fellowship Program

Academy of Integrative Health and Medicine
San Diego, CA
Directors: Tieraona Low Dog, MD and Erika
Cappelluti, MD, PhD, MA, FCCP, ABOIM

September 2017-July 2018

Academic Leadership Fellows Program

American Academy of Colleges of Pharmacy
Mentor: Dhiren Thakker, PhD and Bob Blouin,
PharmD

August 2016-May 2017

Faculty Administrator Development Program

University of North Carolina at Chapel Hill
UNC Center for Faculty Excellence

July 2001 - June 2003

Infectious Diseases Pharmacotherapy Fellow

University of North Carolina at Chapel Hill
School of Pharmacy
Director: Angela D.M. Kashuba, BScPhm, PharmD,
DABCP

July 2000 - June 2001

***Infectious Diseases Pharmacy Resident
Clinical Instructor, School of Pharmacy***
University of North Carolina at Chapel Hill
UNC Healthcare
Co-Directors:
Ralph H. Raasch, PharmD, BCPS, FACCP
John C. Rublein, PharmD, BCPS

July 1999 - June 2000

Pharmacy Practice Resident
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina
Director: James R. Beardsley, PharmD, BCPS

August 1995 - May 1999

Doctor of Pharmacy
Campbell University
School of Pharmacy
Buies Creek, North Carolina

August 1990 - December 1994

Bachelor of Science in Chemistry
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

LICENSURE AND CERTIFICATIONS

October 2013-present

New Foundations in Herbal Medicine
Tieraona Low Dog, MD

November 2015

Healing Touch Level 1 Training, Healing Beyond
Borders, Denise DeForest Pastoor, CHTP/I, APRN,
BC

February 2015

Eden Energy Medicine 101 and 102 with Renata
McConnell, EEM-AP

February 2014

Quantum Crystalline Reiki II Training

September 2013

Certified Quantum Crystalline Reiki I Training

Oct 2011

Certified Reiki Master

May 2011

Reiki II Training

February 2011

Reiki I Training

March 2011-Oct 2011

Registered Veda Vinyasa Yoga Teacher, RYT 230

June 2012-March 2014

North Carolina Clinical Pharmacist Practitioner

<i>October 2008-Dec 2012</i>	American Academy of HIV Medicine-HIV Subject Matter Expert
<i>October 2003-present</i>	Board Certified Pharmacotherapy Specialist
<i>June 1999 - Present</i>	Licensed Pharmacist State of North Carolina #14881

ADDITIONAL APPOINTMENTS

<i>Sept 2015-present</i>	Special Government Employee Antimicrobial Drugs Advisory Committee (ADAC) Food and Drug Administration
<i>Jan 2012-present</i>	Editorial Board Member Biomedical Research International
<i>Dec 2011-Feb 2015</i>	Special Government Employee Antiviral Drugs Advisory Committee (AVDAC) Food and Drug Administration
<i>April 2011-present</i>	Lexi-Comp, Inc., Clinical Expert Advisor and Reviewer
<i>Jan 2011-present</i>	General Supervisor, CAP-accredited UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Lab

PROFESSIONAL AFFILIATIONS

1. American Pharmaceutical Association (*2018-present*)
2. Academy of Integrative Health and Medicine (*2015-present*)
3. International Pharmaceutical Federation (FIP) (*2015-present*)
4. University of North Carolina, Center for AIDS Research (*2003 - present*)
5. Adult AIDS Clinical Trials Group (*2004 - present*)
6. American College of Clinical Pharmacy, Infectious Diseases PRN (*2003 - present*)
7. American Association of Colleges of Pharmacy (*2003-present*)
8. Triangle College of Clinical Pharmacy (*2005 - 2013*)
9. Infectious Diseases Society of America (*2002 - 2006*)
10. International AIDS Society (*2002 - 2006*)
11. Society of Infectious Diseases Pharmacists (*2000 - 2010*)
12. American College of Clinical Pharmacy (*1999 - present*)
13. North Carolina Association of Pharmacists (*1999 - 2010*)
14. Kappa Psi Pharmaceutical Fraternity (*1997 - present*)
15. Phi Lambda Sigma Leadership Society (*1996 - 1999*)
16. American Society of Health System Pharmacists (*1995 - 2002*)
17. Gilead Sciences Advisory Board (*2006 – 2009*)
18. Abbott Laboratories Advisory Board (*2006 - 2009*)
19. Bristol Meyers Squibb Advisory Board (*2007 - 2009*)

GRANTS and CONTRACTS FUNDED

1. Chi B, Principal Investigator. **Corbett A, Mentor.** UJMT Fogarty Global Health Training Program. NIH. December 2016.
2. Stringer J, Principal Investigator. **Corbett A, Co-investigator.** Feasibility of vaginal progesterone to reduce preterm birth among Zambian women receiving antiretroviral therapy in pregnancy. NIH. July 2016
3. Tang J, Principal Investigator. **Corbett A, Co-investigator.** A randomized trial of the levonorgestrel implant versus depot medroxyprogesterone acetate injectable among HIV-infected women receiving efavirenz. NIH. Nov 2016
4. **Corbett A, UNC Project Vietnam Site Pharmacologist.** HPTN 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men. HIV Prevention Trials Network, NIH. April 2016.
5. Ngongondo M, Principal Investigator. **Corbett A, Co-investigator.** A pharmacokinetic evaluation of TDF and ATV exposure in HIV exposed breastfeeding infants of mothers taking TDF/FTC/ATV/r. International AIDS Society Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) April 2016. \$145,800.
6. Tang J, Principal Investigator. **Corbett A, Co-investigator.** Pharmacokinetic interactions between efavirenz, rifampicin, and the levonorgestrel contraceptive implant. NIH NIAID Center for AIDS Research Supplemental Grant. August 2014. \$100,000
7. Kapito-Tembo A, Principal Investigator. **Corbett A, Co-investigator** Pharmacovigilance of infants exposed to antiretroviral drugs given to HIV-infected mothers during breastfeeding. International AIDS Society Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) and World Health Organization April 2014. \$100,000
8. **Corbett A, Principal Investigator.** Roshdy, D, Co-Investigator. DPET 811: Infectious Diseases Learning Activity. December 2013. \$938.
9. Tang J, Principal Investigator. **Corbett A, Co-investigator.** A randomized clinical trial on the effects of progestin based contraception in the genital tract of HIV-infected and HIV-uninfected women. Centers for Disease Control and Prevention. Oct 2013. \$400,000
10. **Corbett A, Principal Investigator.** Nicol, M, Co-Investigator. HIV On-line Pre-Class Activity. UNC Eshelman School of Pharmacy Instructional Innovation September 2013. \$1625.

11. Fiscus S, Principal Investigator. **Corbett A, Co-Investigator.** Breast milk Transmission of HIV: Virology, Pharmacokinetics, and Adherence in BAN. NIH NIAID R56 AI091647-01 September 2010. \$269,079.
12. Dumond J, **Corbett A, Co-Investigator.** Extracellular and Intracellular Atripla (Tenofovir/Emtricitabine/Efavirenz) Pharmacokinetics in the Aging HIV-Infected Population. NC TraCS Institute, March 19, 2010. \$50,000
13. Dumond J, **Corbett A, Co-Investigator.** Atripla pharmacokinetics in the aging HIV-infected population. Society of Infectious Diseases Pharmacists, September 2009. \$10,000
14. Jackson A, **Corbett A, Co-Investigator.** A randomized controlled clinical trial to evaluate high dose fluconazole with short course amphotericin B, with or without flucytosine in the treatment of HIV-associated cryptococcal meningitis. The British Department of International Development. June 2009. \$164,593
15. van Rie A, **Corbett, A, Co-Investigator.** Impact of malnutrition on TB IRIS and pharmacokinetics of TB and HIV co-treatment. NIH/NICHD. October 2008 - September 2013. \$1,000,000.
16. **Corbett A, Principal Investigator.** Pharmacokinetics of Lopinavir/ritonavir in Breast milk and Breastfeeding Infants. Abbott Laboratories. October 2008 - December 2009. \$31,000.
17. **Corbett A, Principal Investigator.** Characterization of novel antiretroviral resistance among HIV-infected patients in the UNC-CH cohort. Virco Laboratories. May 2008 - December 2009. \$15,000.
18. Kashuba ADM, Principal investigator. **Corbett, A, Co-Investigator.** Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine with or without Tenofovir on the Pharmacokinetics of Atazanavir when given with Ritonavir in HIV-Infected Subjects. Bristol-Myers Squibb Company. November 2006 - June 2007. \$187,932.
19. van der Horst C, Principal investigator. **Corbett, A, Co-Investigator.** HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health. Centers for Disease Control, Special Interest Project 13-01. October 2001 - September 2014. \$800,000.
20. Quinlivan EB, Principal investigator. **Corbett, A, Co-Investigator.** Ryan White Comprehensive AIDS Resources Emergency Act Title III Grant. US DHHS/Health Resources and Services Administration/HIV/AIDS Bureau. September 2006 - March 2012.
21. **Corbett A, Principal Investigator.** American College of Clinical Pharmacy, Sanofi-Aventis Infectious Diseases Investigator Development Research Award. Antiretroviral Pharmacology in Malawian Children. July 2004 - June 2005. \$15,000.

22. **Corbett A, Principal Investigator.** UNC University Research Council Research Grant. Antiretroviral Pharmacology in Malawian Children. University of North Carolina, University Research Council. May 2004 - April 2006. \$3961.
23. **Corbett A, Principal Investigator.** UNC Center for AIDS Research Developmental Award. Pharmacokinetic comparison of two generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian children: Triomune tablets versus generic liquids versus trade liquids. University of North Carolina, CFAR. June 2004 - May 2005. \$11,526.
24. **Corbett A, Principal Investigator.** UNC School of Pharmacy Faculty Seed Grant. Pharmacokinetic comparison of two generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian children: Triomune tablets versus generic liquids versus trade liquids. University of North Carolina, School of Pharmacy and Pharmacy Foundation of North Carolina. April 2004 - May 2005. \$9700.
25. **Corbett A, Principal Investigator.** Junior Development Award. Antiretroviral Pharmacokinetics in Malawian Children. University of North Carolina, Committee on Faculty Research and Study Leaves. January 2004 - December 2004. \$5000.
26. Swanstrom R, Principal Investigator, **Corbett A, Co-Investigator.** UNC Center for AIDS Research. Pharmacology Core E. NIH DAIDS P30-HD37260 2006-Current. \$299,556
27. Kashuba ADM, Principal investigator, **Corbett A, Co-Investigator.** University of North Carolina ACTU Pharmacology Support Laboratory. Adult AIDS Clinical Trials Group. DAIDS (NIH). 2004 - 2006. \$280,000.
28. Kashuba, ADM, Principal Investigator, **Corbett A, Co-Investigator.** Eron J, Co-Investigator. The Pharmacokinetic Interaction of a Triple Protease Inhibitor Regimen Containing Fosamprenavir, Lopinavir and Ritonavir in Healthy Volunteers. GlaxoSmithKline (Investigator Initiated Research), 2002 - 2003. \$59,000.
29. Kashuba ADM, Principal Investigator, **Corbett A, Co-Investigator.** Ortho-McNeil Infectious Diseases Academic Fellowship. American College of Clinical Pharmacy. 2002 – 2003. \$20,000.

GRANTS AND CONTRACTS SUBMITTED (NOT FUNDED)

1. Corbett AH, Principal Investigator. Bulfin MP, Steeb D, Greeson A. (Co-investigators). From Nature
2. Wohl, D and Fischer W, Principal Investigators. **Corbett A, Co-investigator.** GS-US 399-1998 A Phase Ib Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of GS-5734 in Subjects with Prior Ebola Virus Disease. Gilead Sciences, Inc. January 2016. \$1,200,000-Terminated by Sponsor

3. van der Horst C, Principal Investigator. **Corbett A, Co-Investigator**. Centers for Disease Control and Prevention SIP. A prospective randomized clinical trial on the effects of different forms of progestin based hormonal contraception on HIV shedding in the female genital tract. Submitted August 2014. Not funded
4. Naidoo A, Principal Investigator. **Corbett A, Co-Investigator**, McIlleron H, Co Investigator. Impact of moxifloxacin co-administration with rifampin in tuberculosis treatment. Submitted April 2014. Not funded.
5. Stuart G, Principal Investigator. **Corbett A, Co-Investigator**. NIH NIAID R21. Outcomes and measures of combined oral contraceptives in HIV-infected women using combined oral contraceptives. Submitted Jan, 2010. Not funded
6. Fiscus S, Principal Investigator. **Corbett A, Co-Investigator**. NIH NIAID R01. Breastmilk Transmission of HIV: Virology, Pharmacokinetics, and Adherence in BAN. Submitted Jan, 2010. Impact/Priority Score: 51.
7. **Corbett A, Principal Investigator**. NIH NIAID Small Research Grant Program (R03) PA-06-180. Influence of Fluconazole and Flucytosine Exposures on Cryptococcal Meningitis. Submitted May, 2009. Impact/Priority Score: 48.
8. Fiscus S, Principal Investigator. **Corbett A, Co-Investigator**. NIH NICHD Grand Opportunities OD09-004. Laboratory Studies to Determine the Reasons for Breast Milk Transmission Despite Use of Antiretrovirals in the BAN Study. Submitted May, 2009. Impact/Priority Score: 59.

RESEARCH INITIATIVES (internally funded)

1. "Implementation of clinic-based nutritional interventions in infectious diseases"
2. Resident Mentored Project and Co-Investigator. "A cross-sectional evaluation of total pill burden, medication discrepancies, and health-related quality of life in patients with HIV at an outpatient infectious diseases clinic"
3. Student Mentored Project. "Evaluation of Abacavir Use and HLA-B*5701 Genotyping in HIV-Infected Patients".
4. Resident Mentored Project. "Characterization of Raltegravir Treated HIV-Infected Patients in an Outpatient Population".
5. PhD Student Mentored Project. "Self-report of Current and Prior Antiretroviral Drug Use in Comparison to the Medical Record Among HIV-infected Patients Receiving Primary HIV Care".
6. Fellow Mentored Project. "Correlations between Drug Metabolizing Enzyme and Drug Transporter Genotypes and Nevirapine Exposure in HIV-Infected Malawian Adults and Children".
7. Resident Mentored Project: "Intervention to Decrease the Frequency of Antiretroviral Related Medication Errors in Hospitalized Patients".

8. Resident Mentored Project: "High-frequency of HIV-related Medication Errors and Associated Risk Factors in Hospitalized Patients".
9. Student Mentored Project: "Evaluation of Dyslipdemia in HIV-infected Patients".
10. Student Mentored Project: "Effects of Optimal Psychiatric Management of Depression in HIV-infected Patients on Associated Virologic and Immunologic Outcomes".
11. Resident Mentored Project: "Analysis of the Impact of Understudied Barriers to Medication Access on Adherence in Indigent HIV-infected Patients".
12. "Early access of MK-0518 in combination with an optimized background antiretroviral therapy (OBT) in highly treatment experienced HIV-1 infected patients with limited or not treatment options".
13. "Early access of TMC125 in combination with other antiretrovirals in treatment experienced HIV-1 infected subjects with limited treatment options".
14. "Pharmacokinetic comparison of two generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV infected Malawian children: Triomune™ tablets versus generic liquids versus trade liquids" in collaboration with Mina Hosseinipour, MD; Peter Kazembe, MD; Irving Hoffman, PA.
15. "Assessment of pharmacologic treatments of HIV/AIDS and associated outcomes using the North Carolina-AIDS drug assistance program (ADAP) database" in collaboration with Emily Brouwer (PharmD candidate); Peter Leone, MD; Sonia Napravnik, PhD.
16. "A retrospective comparative analysis of the immunologic and virologic response to Fuzeon™ (enfuvirtide; T-20) versus optimized background in HIV infected patients-after the TORO trials" in collaboration with Leslie Prichard(PharmD candidate), Sonia Napravnik, PhD; Joseph Eron, MD; Prema Menezes, PA.
17. Protocol Pharmacologist for "ACTG 5221: A strategy study of immediate versus deferred initiation of antiretroviral therapy for HIV-infected persons treated for tuberculosis with CD4<200cells/mm³".
18. Protocol Pharmacologist for "ACTG 5225: A phase I/II dose finding study of high dose fluconazole treatment in AIDS-associated cryptococcal meningitis".
19. Co-investigator and Coordinator for "BI 1182.70: An open-label non-randomized treatment protocol of tipranavir co-administered with low dose ritonavir (TPV/r) in protease inhibitor-experienced patients with HIV-1 infection (the tipranavir expanded access program)".
20. Co-investigator and Coordinator for "A comparison of alternative injection devices to the standard subcutaneous needle/syringe combination for enfuvirtide (Fuzeon®)".

MANUSCRIPTS AND REVIEWS

1. Bruce RD, Merlin J, Lum PJ, Ahmed E, Alexander C, **Corbett AH**, Foley K, Leonard K, Triesman GJ, Selwyn P. 2017 HIVMA of IDSA clinical practice guideline for the management of chronic pain in patients living with HIV. *Clin Infect Dis* 2017;65(10):e1-37.
2. Kourtis AK, Haddad L, Tang J, Chinula L, Hurst S, Wiener J, Ellington S, Nelson, JAE, **Corbett A**, De Paris K, King CC, Hosseinipour M, Hoffman IF, and Jamieson DJ. A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: addressing evolving research priorities. *Contemp Clin Trials*. 2017;52:27-34.
3. Price JT, Mollan KR, Fuseini NM, Freeman BL, Mulenga HB, **Corbett AH**, Vwalika B, Stringer JSA. Vaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocol. *Pilot Feasibility Stud.* 2017 Jul 18;4:21.
4. Asher G, **Corbett A**, Hawke R. Common dietary supplement-drug interactions. *American Family Physician.* 2017 Jul 15;96(2):101-107.
5. Flax V, **Corbett A**, et al. Plasma micronutrient concentrations are altered by antiretroviral therapy and lipid based nutrient supplements in lactating HIV-infected Malawian women. *Journal of Nutrition* Aug 2015;145(8):1950-7.
6. Zhou S, Martin K, **Corbett A**, et al. Total daily pill burden in HIV-infected patients in the US South. *AIDS Patient Care and STDs* 2014;28(6):311-317.
7. **Corbett A**, Kayira D, Kashuba A, White N, Kourtis A, Chasela C, Martinson F, Phiri G, Musisi B, Kamwendo D, Hudgens M, Hosseinipour M, van der Horst V. Pharmacokinetics of HAART in mothers and breastfeeding infants from 6-24 weeks post partum. *Antiviral Therapy* 2014;19(6):587-95 [Epub ahead of print Jan 2014].
8. Dumond J, **Corbett AH**, Kashuba ADM, et al. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. *HIV Med* 2013 Aug;14(7):401-9.
9. **Corbett AH**. Antiretroviral pharmacology in breast milk. *Adv Exp Med Biol* 2012;743:109-18.
10. Daniels L, Raasch R, **Corbett A**. Frequency of antiretroviral related medication errors in hospitalized patients after the implementation of several interventions. *Am J Health Syst Pharm* 2012;69(5):422-30.
11. Brown K, Hosseinipour M, Hoskins J, Tien H, Kazembe P, McLeod H, Kashuba A, **Corbett A**. Genotype correlation in nevirapine exposures in Malawians. *Pharmacogenomics* 2012;13(1):113-121.
12. Heil E, **Corbett A**. Guidelines for the use of extended-release nevirapine in HIV-infected patients. *Expert Opin pharmacother* 2011; epub ahead of print.

13. Stuart G, Moses A, **Corbett A**, PHiri G, Kumwenda W, Mkandwire N, Chintedze J, Hosseinipour M, Hoffman I, Stanczyk F, and Kashuba A. Pharmacokinetic and pharmacodynamic activity of the combined oral contraceptive (COC) LoFemenal (norgestrel 300mcg/ethinyl estradiol 30mcg) in HIV+ women in Lilongwe, Malawi *JAIDS* 2011;58(2):e40-e43.
14. Brouwer E, Napravnik S, Smmiley SG, **Corbett AH**, Eron JJ. Self report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care. *Pharmacoepidemiol a Drug Saf* 2011;20:432-9.
15. Heil E, Eron J, Shredzinski E, Corbett A. Therapeutic drug monitoring of antiretroviral drugs during extracorporeal membrane oxygenation in an HIV-infected patient with influenza-A (H1N1) [in progress for *AIDS*].
16. **Corbett A**, Hosseinipour MC, Nyirenda J, Kanyama C, Rezk N, Mkupani P, Sichali D, Tien H, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian children. *Antiviral Therapy* 2010;15(1):83-90.
17. McRae MP, Rezk N, Bridges A, **Corbett A**, Tien H-C, Brouwer K, and Kashuba ADM. Plasma bile acid concentrations in HIV infected subjects taking protease inhibitor therapy: possible implications for hepatotoxicity. *Pharmacotherapy* 2010;30(1):17-24.
18. Pastakia S, **Corbett A**, Raasch R, Napravnik S, Correll T. High frequency of HIV related medication errors and associated risk factors in hospitalized patients. *Annals of Pharmacotherapy* 2008;42(4):491-7.
19. Jung B, Rezk N, Bridges A, **Corbett A**, Kashuba A. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. *Biomed Chromatogr* 2007;21:1095-1104.
20. Dumond J, Yeh R, Patterson K, **Corbett A**, Jung B, Rezk N, Bridges A, Stewart S, Cohen M, Kashuba A. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. *AIDS* 2007;21(14):1899-907.
21. Hosseinipour MC, **Corbett A**, Kanyama C, Mshali I, Phakati S, Rezk NL, van der Horst C, and Kashuba ADM. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV infection in Malawi. *AIDS* 2007;21(1):59-64.
22. **Corbett A**, Patterson KB, Tien HC, Kalvass LA, Eron JJ, Ngo LT, Lim ML, Kashuba ADM. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. *Antimicrob Agents Chemother* 2006;50:2756-61.
23. Min SS, **Corbett A**, Rezk NL, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS,

- Kashuba ADM. Protease inhibitor and non-nucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1 infected women. *J Acquir Immun Defic Syndr* 2004;37:1577-80.
24. **Corbett A**, Eron JJ, Fiscus SA, Rezk NL, Kashuba ADM. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. *J Acquir Immun Defic Syndr* 2004;36:921-928.
 25. **Corbett A**, Lim ML, Kashuba, ADM. Kaletra™ (Lopinavir/Ritonavir). *Annals of Pharmacotherapy*, 2002;36(7/8):1193-1203.
 26. **Corbett A**, Kashuba ADM. Fosamprenavir. *Current Opinion in Investigational Drugs*, 2002;3(3):384-390.
 27. **Corbett A**, Rublein JC. DAPD. *Current Opinion in Investigational Drugs*, 2001;2(3):348-353.
 28. **Corbett A**. Treatment of End Stage AIDS. *Pharmacy Times* 2000;47,48,53.
 29. Farina RD, **Corbett A**, Edwards MD, Kendrick SM. Osteoporosis Screening: is screening effective? Can it be done economically? Will people pay for it? *U.S. Pharmacist*, 1999;24(9):38-43.
 30. Barnes CL, **Corbett A**, Carter SA. Drug-Induced Hypoglycemia. *U.S. Pharmacist*, 1999;24(2):41-50.
 31. Welch TW, Corbett AH, Thorp HH. Electrochemical determination of nucleic acid diffusion coefficients through noncovalent association of a redox-active probe. *Journal of Physical Chemistry* 1995;99(30):11757-11763.

CHAPTERS AND ON-LINE PUBLICATIONS

1. Heil EL, Banoub MF, **Corbett A**. Human Immunodeficiency Virus in *Pharmacotherapy: Principles and Practice* (5th Edition) 2017.
2. Heil EL, **Corbett A**. Opportunistic Infections in HIV Infected Patients in 10th Edition of *Applied Therapeutics : The Clinical Use of Drugs* (2016)
3. Heil EL, Trezza C, **Corbett A**. Human Immunodeficiency Virus in *Pharmacotherapy: Principles and Practice* (4th Edition) 2014.
4. **Corbett A**. Complementary and Alternative Medicine in ACSAP 2013 Book 1 Pulmonary and Preventive Care, January 2013.
5. **Corbett A**, Adams J, Dumond J, Kashuba A. Human Immunodeficiency Virus Infection in *Pharmacotherapy: Principles and Practice* (3rd Edition) 2012.
6. **Corbett A**. Human Immunodeficiency Virus in *Pharmacotherapy Principles and Practice Study Guide* (3rd Edition) 2012.

7. **Corbett A.** Antiretroviral pharmacology in breast milk in *Human Immunodeficiency Virus-1 and Breastfeeding: Biology, Research Advances and Policy* (1st Edition) 2012.
8. **Corbett A,** Adams J, Dumond J, Kashuba A. Human Immunodeficiency Virus Infection in *Pharmacotherapy: Principles and Practice* (3rd Edition) 2011.
9. **Corbett A** and Heil E. Opportunistic Infections in HIV Infected Patients in 9th Edition of *Applied Therapeutics : The Clinical Use of Drugs* (2011).
10. **Corbett A.** Retrovirus in *World Book Encyclopedia* (2011).
11. **Corbett A** Protease Inhibitors in *World Book Encyclopedia* (2011).
12. **Corbett A,** Sheffield C. Key pharmacologic principles and drug-drug interactions in HIV patient care. October 2010-present (updated every 6 months). Clinical Care Options In Practice.
13. **Corbett A,** Sheffield C. HIV Infection in *Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach* 2010 (1st Edition).
14. **Corbett A,** Dumond J. Key pharmacologic principles and drug-drug interactions in HIV patient care. October 2009. Clinical Care Options.
15. **Corbett A,** Yeh R, Dumond J, Kashuba A. Human Immunodeficiency Virus Infection in *Pharmacotherapy: A Pathophysiological Approach and Pharmacotherapy Principles and Practice* (2th Edition) 2009.
16. Pastakia S, **Corbett A,** Raasch R, Napravnik S, Correll T. Frequency of HIV-related medication errors and associated risk factors in hospitalized patients. July 2008. <http://www.medscape.com/viewarticle/576143>.
17. **Corbett A.** Opportunistic Infections in HIV Infected Patients in 9th Edition of *Applied Therapeutics : The Clinical Use of Drugs* (2008).
18. **Corbett A,** Yeh R, Dumond J, Kashuba A. Human Immunodeficiency Virus Infection in *Pharmacotherapy: A Pathophysiological Approach and Pharmacotherapy Principles and Practice* (1st Edition).
19. Catanzaro L, **Corbett A,** Kashuba A, Shafer R, Hewitt RG, Acosta E, and Morse GD. HIV-1 Protease Inhibitors, in *Antimicrobial Therapy and Vaccines, Vol. II*. Yu VL, et al. (eds), New York: Apple Trees Production, 2003.
20. **Corbett A,** Kashuba ADM. Ask the Experts - Combining Saquinavir with Lopinavir/ritonavir. www.medscape.com, September 2002.
21. **Corbett A,** Kashuba ADM. Ask the Experts - Treatment of Nelfinavir-Associated Diarrhea. www.medscape.com, January 2002.

SCIENTIFIC ABSTRACTS

1. Cottrell M, **Corbett AH**, Chinula L, Msika A, Tegha G, Stanczyk F, Kourtis AP. Female genital tract efavirenz exposure negatively correlates with serum estradiol levels in Malawian women. 22nd International AIDS Conference. July 2018.
2. Ngongondo M, Corbett A, Kapito-Tembo A, Hosseinipour M. A pharmacokinetic evaluation of TDF and ATV exposure in HIV exposed breastfeeding infants of mothers taking TDF/3TC/ATV/r. 22nd International AIDS Conference. July 2018.
3. Duong R, **Corbett A**. Implementation of clinic-based nutritional interventions in an infectious diseases clinic. ASHP Midyear Clinical Meeting Dec 2014.
4. Dumond JB, Adams JL, Prince HMA, Kendrick R, White N, Sykes C, **Corbett AH**, Patterson KB, Forrest A, Kashuba ADM. Tenofovir diphosphate (TFV-DP) and Emtricitabine triphosphate (FTC-TP) pharmacokinetics (PK) in older HIV+ patients. 13th International Workshop on Clinical Pharmacology of HIV Therapy. Apr 2012 [Oral presentation and poster].
5. Dumond JB, Adams JL, Prince HMA, Kendrick R, White N, Sykes C, **Corbett AH**, Patterson KB, Forrest A, Kashuba ADM. Tenofovir diphosphate (TFV-DP) and Emtricitabine triphosphate (FTC-TP) pharmacokinetics (PK) in older HIV+ patients: a pilot study. 2nd International Workshop on HIV and Aging. Oct 2011 [Oral presentation].
6. **Corbett A** and Williams D. Introduction of an integrative medicine elective at the UNC Eshelman School of Pharmacy. American Association of Colleges of Pharmacy Annual Meeting. July 2011 [Poster presentation].
7. Stuart G, Moses A, **Corbett A**, Phiri G, Kumwenda W, Mkandwire N, Chintedze J, Hosseinipour M, Stanczyk F, Kashuba A. Pharmacokinetic (PK) and Pharmacodynamic (PD) Activity of the Combined Oral Contraceptive (COCs) LoFemenal (Norgestrel 300ug/Ethinyl Estradiol 30ug) in HIV-Infected Women in Lilongwe, Malawi. 18th Conference on Retroviruses and Opportunistic Infections, February 2011. [Poster U-151].
8. **Corbett A**, Kayira D, Kashuba A, White N, Kourtis A, Chasela C, Martinson F, Phiri G, Musisi B, Kamwendo D, Hudgens M, Hosseinipour M, van der Horst V. Pharmacokinetics of HAART in mothers and breastfeeding infants from 6-24 weeks post partum. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 2010 [Poster].
9. Wrenn R, **Corbett A**, Weiner J, Chasela C, Martinson F, Kayira D, Tegha M, Kamwendo D, Hudgens M, and van der Horst C. Methods to assess adherence to antiretroviral prophylaxis in breastfed infants: the BAN study. North Carolina Association of Pharmacists, March 2010 [Poster].
10. Lewis P, Brouwer E, Raasch R, **Corbett A**. Characterization of raltegravir treated HIV-infected patients in an outpatient population. South Eastern Residency Conference, April 2009 [Oral presentation].

11. Mitchell JM, Brouwer E, McLeod H, **Corbett A**. Evaluation of abacavir use in HIV-infected patients: utilization of HLA-B*5701 genotype. North Carolina Association of Pharmacists, March 2009 [Poster].
12. **Corbett A**, Chasela C, Martinson F, Rezk N, Kashuba A, Jamieson D, Kayira D, Tegha G, Kamwendo D, van der Horst C, and the BAN Study Team. Lopinavir/ritonavir concentrations in breast milk and breastfeeding infants. 16th Conference on Retroviruses and Opportunistic Infections, February 2009. [Poster T-139].
13. Mayer L, Raasch R, **Corbett A**. Intervention to decrease the frequency of antiretroviral (ARV)-related errors in hospitalized patients. 43rd ASHP Midyear Clinical Meeting, Orlando, Florida, December 2008.
14. Brouwer E, Napravnik S, **Corbett A**, Eron J. A validation study of self-reported antiretroviral use within a clinical cohort of HIV positive patients. 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Copenhagen, Denmark, August 17-20, 2008 [Platform presentation].
15. Davis M, Mayer L, Karwa R, Brouwer E, Correll T, Napravnik S, Quinlivan B, **Corbett A**. Evaluation of dyslipidemia in and HIV-infected population. North Carolina Association of Pharmacists, April 2008 [Platform presentation].
16. Bertino J, Vila T, Cala S, **Corbett A**. Effects of Optimal Psychiatric Management of Depression in HIV-infected Patients on Associated Virologic and Immunologic Outcomes. North Carolina Association of Pharmacists, April 2008 [Poster presentation].
17. Bertino J, Vila T, Cala S, **Corbett A**. Effects of Optimal Psychiatric Management of Depression in HIV-infected Patients on Associated Virologic and Immunologic Outcomes. College of Psychiatric and Neurologic Pharmacists 2008 Annual Meeting, April 13-16 [Poster presentation].
18. Brown K, Hosseinipour M, Hoskins J, Tien H-C, Rezk N, Kazembe P, Weigel R, McLeod H, Kashuba ADM, **Corbett A**. Correlations between drug metabolizing enzyme and drug transporter genotypes and nevirapine exposure in HIV-infected Malawian adults and children. 9th International Workshop on Clinical Pharmacology of HIV Therapy April 2008 [Poster P1].
19. Vila T, Cala S, **Corbett A**. Effects of optimal medication therapy management of depression in human immunodeficiency virus (HIV) infected patients on associated virologic and immunologic outcomes. North Carolina Association of Pharmacists, April 2008 [Poster presentation].
20. **Corbett A**, Martinson F, Rezk N, Kashuba A, Jamieson D, Chasela C, Hyde L, Ahmed Y, Tegha G, Joaki G, Kamwendo D, van der Horst C. Antiretroviral drug concentrations in breast milk and breastfeeding infants. 15th Conference on Retroviruses and Opportunistic Infections, February 2008 [Poster 648].

21. Brouwer E, **Corbett A**, Napravnik S. Poor recall of antiretroviral use among patients infected with HIV. North Carolina Association of Pharmacists, April 2007 [Poster presentation].
22. Brown K, **Corbett A**, Hosseinipour M, McLeod H, Kashuba ADM. The relationship between drug metabolizing enzyme and drug transporter genotypes and nevirapine exposure in HIV-infected Malawian adults and children. North Carolina Association of Pharmacists, April 2007 [Poster presentation].
23. Karwa R, Correll T, Raasch R, **Corbett A**. Evaluation of dyslipidemia in an HIV population. American Society of Health Systems Pharmacy Midyear Clinical Meeting, December 2006 [Poster presentation].
24. Villa T, Cala S, **Corbett A**. Effects of optimal medication therapy management of depression in human immunodeficiency (HIV) infected patients on associated virologic and immunologic outcomes. American Society of Health Systems Pharmacy Midyear Clinical Meeting, December 2006 [Poster presentation].
25. **Corbett A**, Hosseinipour M, Nyirenda J, Knayama C, Mshali I, Chinyama S, Lyke A, Rezk N, Hoffman I, Kashbua A, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics (PK) Of Trade and Generic Liquid and Split Tablet Formulations of Lamivudine, Stavudine, and Nevirapine in HIV-Infected Malawian Children. 2006 Annual American College of Clinical Pharmacy, St. Louis, MO, October 2006 [Poster 408].
26. Pastakia S, **Corbett A**, Raasch R, Napravnik S, and Correll T. Evaluation of continuity of HIV care from the outpatient to the inpatient setting. 2007 American College of Clinical Pharmacy Annual Meeting, St Louis, Missouri, October 2006 [Poster 369].
27. Dumond J, Yeh R, Patterson K, **Corbett A**, Jung B, Rezk N, Bridges A, Dempsey E, Cohen M, Kashuba A. First Dose and Steady-State Genital Tract Pharmacokinetics of Ten Antiretroviral Drugs in HIV-Infected Women: Implications for Pre- and Post-Exposure Prophylaxis. 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, February 2006 [Oral Presentation 129].
28. Yeh R, **Corbett A**, Jung B, Rezk N, Bridges A, Min S, Cohen M. Kashuba ADM. First Dose and Steady-State Genital Tract Pharmacokinetics of Zidovudine, Lamivudine, and Efavirenz in HIV-infected Women. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., December 2005.
29. **Corbett A**, Hosseinipour M, Nyirenda J, Knayama C, Mshali I, Chinyama S, Lyke A, Rezk N, Hoffman I, Kashbua A, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics (PK) Of Trade and Generic Liquid and Split Tablet Formulations of Lamivudine, Stavudine, and Nevirapine in HIV-Infected Malawian Children. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 2005 [Poster H-1106].

30. Hosseinipour, MC, **Corbett A**, Kanyama C, Mshali I, Chinyama S, Phakati S, Rezk N, White S, Hoffman I, Van der Horst C, Kashuba ADM. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian subjects. 12th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 2005 [Poster 631].
31. **Corbett A**, Davidson L, Park J, Patterson K, Eron JJ, Ngo L, Lim ML, Shelton M, Wire MB, and Kashuba ADM. Dose separation strategies to overcome the pharmacokinetic (PK) interaction of a triple protease inhibitor regimen containing fosamprenavir (908), lopinavir (LPV), and ritonavir (RTV). 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 2004 [Poster 611].
32. **Corbett A**, Eron JJ, Fiscus SA, Rezk N, and Kashuba A. Pharmacokinetics, Efficacy, and Safety of a Triple Protease Inhibitor Salvage Regimen Containing Amprenavir/Saquinavir/Ritonavir. American College of Clinical Pharmacy, Annual Meeting, Atlanta, Georgia 2003 [Platform Presentation].
33. **Corbett A**, Eron J, Diebold M, Fiscus S, Rezk N, Kashuba A. Short-term Safety and Efficacy of an Amprenavir [APV] /Saquinavir [SQV] /Ritonavir [RTV] Salvage Regimen. Infectious Diseases Society of America, Chicago, Illinois 2002 [Poster 450].
34. **Corbett A**, Eron J, Rezk N, Diebold M, Kashuba A. A Triple Protease Inhibitor [PI] Salvage Regimen of Amprenavir [APV] + Saquinavir [SQV] + Ritonavir[RTV]: Steady State [SS] Pharmacokinetics [PK] and Initial RNA and CD4 Response. World AIDS Conference, Barcelona, Spain 2002 [Poster 4464].
35. Min SS, **Corbett A**, Rezk N, Fiscus SA, Cohen MS, Kashuba ADM. Differential Penetration of Protease Inhibitors [PI] and Non-Nucleoside Reverse Transcriptase Inhibitors [NNRTI] into the Female Genital Tract [GT]. World AIDS Conference, Barcelona, Spain 2002 [Poster 5966].
36. Kashuba ADM, Min SS, **Corbett A**, Rezk N, Cohen MS. Comparison of Protease Inhibitor [PI] and Non-Nucleoside Reverse Transcriptase Inhibitor [NNRTI] Concentrations [CONC] in the Male [M] and Female [F] Genital Tract [GT]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington D.C., 2002 [Poster 5.3].
37. **Corbett A**, Rublein JC, Raasch RH. Impact of HIV Genotyping on Choice of Antiretrovirals. ASHP Midyear Clinical Meeting, Las Vegas, Nevada 2000.
38. **Corbett A**, Martin TA, Ohl CA. Evaluation of Antimicrobial Use in a Level Trauma Intensive Care Unit. ASHP Midyear Clinical Meeting, Las Vegas, Nevada 2000.

HONORS AND AWARDS

<i>May 2012</i>	Pam Herriott Award University of North Carolina Center for AIDS Research
<i>October 2010</i>	American College of Clinical Pharmacy Fellow
<i>May 2007</i>	Pam Herriott Award University of North Carolina Center for AIDS Research
<i>2004</i>	Board Certification in Pharmacotherapy American College of Clinical Pharmacy
<i>2004</i>	American College of Clinical Pharmacy Sanofi-Aventis Infectious Diseases Investigator Development Research Award
<i>2002</i>	American College of Clinical Pharmacy Ortho-McNeil Infectious Diseases Research Fellowship
<i>September 2002</i>	Infectious Diseases Society of America Travel Grant Award
<i>May 1999</i>	ASHP Student Leadership Award
<i>January 1999</i>	DHHS National Innovation in Health Award, Honorable Mention
<i>Fall 1998</i>	ASHP Clinical Skills Competition Second Place for Campbell University
<i>Spring 1998</i>	Phi Lambda Sigma National Leadership Challenge Third Place

OFFICES, SERVICE

<i>Sept 2017-current</i>	Chair, Natural Products Special Interest Group International Pharmaceutical Federation (FIP)
<i>March 2016-Sept 2017</i>	Vice Chair, Natural Products Special Interest Group International Pharmaceutical Federation (FIP)
<i>May 2016-current</i>	UNC Advisory Committee on International Students and Scholars
<i>August 2015-current</i>	UNC Eshelman School of Pharmacy Global Engagement Advisory Committee

<i>September 2014-2016</i>	American College of Clinical Pharmacy Fellows Committee
<i>August 2014-2016</i>	The University of North Carolina Covenant Scholars Mentor
<i>August 2014-2016</i>	UNC Eshelman School of Pharmacy Curriculum Committee
<i>Nov 2013-2016</i>	UNC Eshelman School of Pharmacy HELPRx Committee
<i>Jan 2013-Dec 2013</i>	American Association of Colleges of Pharmacy Faculty Delegate
<i>Oct 2011 – Oct 2013</i>	American College of Clinical Pharmacy 2013 Programming Committee Vice Chair
<i>Oct 2011-Dec 2012</i>	American Association of Colleges of Pharmacy Faculty Alternate Delegate
<i>January 2011-June 2014</i>	UNC Hospitals and UNC Eshelman School of Pharmacy Partnership in Patient Care Ambulatory Care Committee, Co-Chair
<i>October 2010-2011</i>	American College of Clinical Pharmacy Educational Affairs Committee, Member
<i>August 2010-present</i>	Infectious Diseases Society of America HIV Pain Management Guideline Committee, Member
<i>August 2007-June 2014</i>	UNC Eshelman School of Pharmacy Admissions Committee, Member Chair, August 2007-2010
<i>August 2010-present</i>	UNC Eshelman School of Pharmacy Triangle College of Clinical Pharmacy Student Chapter, Faculty Advisor
<i>October 2005 - 2010</i>	American College of Clinical Pharmacy Awards Committee, Vice Chair (2007-2008) Chair (2008-2010)
<i>June 2007 - 2011</i>	Adult AIDS Clinical Trials Group Translational Research and Drug Development Scientific Committee, Member and Pharmacologist
<i>Apr 2007 – June 2011</i>	AIDS Clinical Trials Group

	Member, Translational Research and Drug Development Scientific Committee
<i>October 2006 - present</i>	American College of Clinical Pharmacy StuNet, College of Pharmacy Liaison
<i>October 2006 - 2010</i>	American College of Clinical Pharmacy StuNet, IDPRN Liaison
<i>August 2006 - present</i>	UNC Eshelman School of Pharmacy Scholarship Committee, member
<i>January 2006 - 2012</i>	Triangle College of Clinical Pharmacy Secretary/Treasurer Elect (2006) Secretary/Treasurer (2007) President Elect (June 2008) President (June 2008 - 2009) Member (Jan 2006 to 2010)
<i>October 2005 – Oct 2006</i>	American College of Clinical Pharmacy Infectious Diseases PRN Secretary/Treasurer (2005 - 2006) Member (current)
<i>June 2005 - 2011</i>	UNC School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics Fellowship Steering Committee, Member
<i>January 2005 - May 2007</i>	UNC School of Pharmacy, Infectious Diseases Group, Chair
<i>November 2004 - December 2005</i>	Adult AIDS Clinical Trials Group Maintenance of Drug Interaction Tables, Director
<i>August 2004-2007</i>	UNC Eshelman School of Pharmacy Student Progressions Committee
<i>February 2004 - December 2006</i>	Adult AIDS Clinical Trials Group Opportunistic Infections Subcommittee, Member
<i>January 2004 - 2010</i>	UNC School of Pharmacy Clinical Discussion Group, Faculty Advisor
<i>January 2004 - December 2006</i>	Adult AIDS Clinical Trials Group Pharmacology Committee
<i>July 2004 - August 2007</i>	UNC School of Pharmacy, Progressions Committee Member
<i>February 2004 – 2009</i>	<i>iMedOptions.com</i>

	Capsule Summary Author
<i>July 2003 - May 2007</i>	UNC School of Pharmacy, Class of 2007 Faculty Advisor
<i>August 2004 - January 2005</i>	Kappa Epsilon, UNC Chapter Faculty Advisor
<i>1997 - 1998</i>	ASHP Student Forum Communications Committee
<i>1996 - 1997</i>	SSHP Campbell University Vice President Chair- ASHP Midyear Meeting Committee
<i>1997 - 1998</i>	Phi Lambda Sigma, Campbell University Vice President
<i>1997</i>	Kappa Psi Pharmaceutical Fraternity Vice President Pledge Class Fund Raising Committee

PRECEPTING/MENTORING:

North Carolina AIDS Education and Training Center: NC Rural HIV Care Mini-Residency

Nov 2013-current	Pharmacist Preceptorships Minh Pharm, PharmD Leslie Sanderson, PharmD Treva Stevens, PharmD Krutika Mediwala Eunice Eun, PharmD Jenna Reel, PharmD Mackie King, PharmD Michael Ilodigwe, PharmD
------------------	---

UNC School of Pharmacy PhD Candidates (precepting, student advisory and dissertation committees)

July 2018-present	Aaron Devanathan (student advisory committee member)
Nov 2015-2018	Jingxian Chen (dissertation advisory committee member)
Nov 2015-present	Nithya Srinivas (dissertation advisory committee member)
May 2013-017	Corbin Thompson (student advisory committee member, dissertation advisory committee member and ID clinic rotation)
May 2012-Aug 2013 Jan 2011-July 2014	Brandon Gufford (ID/IM clinic rotation) Melanie Nicol (dissertation committee member and ID clinic clinical advisor)
May 2010-July 2014	Melanie Nicol (ID clinic rotation and student advisory committee member)

May 2009	Nathan Pfeifer (ID clinic rotation)
April 2009 – Dec 2011	Tae Eun Kim (student advisory committee member and dissertation committee member)
August 2008 – 2012	LaToya Griffin (student advisory committee member and dissertation committee member)
January 2009 - June 2009	Sunita Paul (student advisory committee member)
August 2008- December 2008	Christina Santos (ID clinic rotation)

UNC Hospitals Infectious Diseases and Pharmacy Practice Residents

July 2015-June 2016	Whitney Davis, PharmD
July 2014-June 2015	Jacqueline Isip, PharmD
July 2013-July 2014	Danya Roshdy, PharmD
July 2012-June 2013	Nicole Nicolsen, PharmD
July 2011-June 2012	Kelly Martin, PharmD
July 2010-June 2011	Emily Heil, PharmD
July 2009 – June 2010	Lisa Fletcher, PharmD Emily Heil, PharmD Caroline Tee, PharmD Cameron Mitchell, PharmD
July 2008 - June 2009	Paul Lewis, PharmD
July 2007 - June 2008	Lindsay Mayer, PharmD
July 2006 - June 2007	Rakhi Karwa, PharmD
July 2005 - June 2006	Sonak Pastakia, PharmD
July 2004 - June 2005	Will Musick, PharmD, BCPS
January 2004 - June 2004	Todd Correll, PharmD, BCPS

UNC School of Pharmacy Fellows (clinical advisor)

Jan 2017-Present	Thamer Almangour, PharmD
Sept 2012-June 2015	Mackenzie Cottrell
July 2010-June 2012	Jessica Adams, PharmD
July 2007 – June 2010	Kevin Brown, PharmD
July 2005 - June 2007	Julie Dumond, PharmD Kan Lu, PharmD
September 2004 - June 2005	Lakshmi Vassist, PharmD
July 2003 - June 2005	Rosa Yeh, PharmD, BCPS

***UNC School of Pharmacy Honors Program and
UNC School of Pharmacy Infectious Disease Group***

Dec 2011-April 2012	Angela Kim, PharmD candidate
Apr-May 2011	Melissa Hunter, PharmD candidate
June 2005 - May 2007	Leslie Prichard, PharmD
March 2005 - June 2007	Emily Brouwer, PharmD
November 2004 - December 2004	Carolina Molina Lowe, PharmD

UNC School of Pharmacy Research Elective

October 2009 – Jan 2010	Ciantel Adair Blyler, PharmD candidate
August 2007 - April 2008	Ryan Owenby, PharmD candidate
June 2004 - December 2004	Jessica Poirier, PharmD candidate Vincent Gaver, PharmD candidate

UNC Clinical Scholars Program

May 2009 – May 2010	Rebekah Wrenn, PharmD candidate
June 2008 –April 2009	Cameron Mitchell, PharmD
April 2008	Emily Wong, PharmD
June 2007 - April 2008	Megan Davis, PharmD
June 2007 - April 2008	Jaimie Bertino, PharmD
June 2006 - April 2007	Tania Vila, PharmD
May 2004 - present	Faculty Mentor

UNC Eshelman School of Pharmacy Teaching Certificate Mentor

August 2014-present	Breanne Roess, PharmD
August 2013-2014	Kristen Gardner, PharmD
August 2012-2013	Farah Khorassani, PharmD
August 2011-2012	Nicole NicholSEN, PharmD

UNC Medical Student Research Program

January 2004 – December 2004	Alison Lyke, PharmD (Holderness Fellowship Recipient)
------------------------------	--

UNC Epidemiology, PhD Candidates

July 2007 – 2013	Emily Brouwer, PharmD
------------------	-----------------------

UNC School of Pharmacy, Clinical Clerkships

HIV Ambulatory Care Rotation

January 2004 - present	Fourth year pharmacy students
------------------------	-------------------------------

COURSE DIRECTOR/CO-DIRECTOR:

1. Course Number: PHCY 733
Course Title: Integrative Pharmacotherapy III
Dates: August 2018- May 2018
2. Course Number: PHCY 504
Course Title: Evidence Based Practice
Dates: August 2015- December 2016
3. Course Number: PHCY 631
Course Title: Integrative Pharmacotherapy I
Dates: August 2016- May 2016
4. Course Number: NURS 609.001
Course Title: Global Health Service Learning to Increase Understanding of Migrant Latino Health
Dates: January 2015-May 2016
5. Course Number: DPET 811
Course Title: Infectious Diseases
Dates: January 2013-April 2016
6. Course Number: DPET 816
Course Title: Integrative Medicine
Dates: August 2010-December 2016
7. Course Number: DPET 810
Course Title: AIDS: Principles, Practices, and Politics
Dates: January 2004 - present

8. Course Number: PUBH 120
Course Title: AIDS: Principles, Practices, and Politics
Dates: Jan 2004 - present (co-coordinator)
9. Course Title: UNC School of Pharmacy, DPET Division
Postdoctoral Fellows Course
Dates: July 2006 - June 2009

COURSE INSTRUCTOR

1. Course Title: School of Medicine, Integrative Medicine Course
Topic: Dietary Supplements: Practical Use
2. Course Title: PHCY 732
Topic: Human Immunodeficiency Virus
3. Course Title: PHCY 733
Topic: Dietary Supplements
4. Course Number: PHCY 510
Course Title: Clinical Pharmacology
Lectures: Dietary Supplements
5. Course Number: PHCY 611
Course Title: Applied Clinical Pharmacology
Lectures: Hepatitis C
6. Course Number: PACS 711 (Physician Assistant's Program)
Course Title: Pharmacology and Therapeutics I
Lectures: HIV and Hepatitis C
7. Course Number: PACS 731 (Physician Assistant's Program)
Course Title: Pharmacology and Therapeutics III
Lectures: Overview of Integrative Medicine
8. Course Number: MEDI 238, UNC School of Medicine
Course Title: Respiratory Block
Lectures: Overview of Clinical Pharmacology
9. Course Number: PHCY 442
Course Title: Introduction to Pharmaceutical Care
Lectures: Integrative Medicine
2011-2015
10. Course Title: Fellows Core Curriculum, UNC School of Medicine
Division of Infectious Diseases
Lectures: Antiretroviral Pharmacology
2006 - present
11. Course Title: HIV 101, UNC AIDS Clinical Trials Group
Lectures: Antiretroviral Pharmacology
2006 - present

12. Course Title: Organisms and Antibiotics, UNC School of Medicine
Lectures: 2008 - 2015
13. Course Number: DPET 840
Course Title: Advanced Pharmacotherapy
Lectures: HIV and Opportunistic Infections
2006 - present
14. Course Number: PHCY 803
Course Title: Ambulatory Care Elective
Lectures: HIV Therapy
2004 - 2015
15. Course Number: DPPE 811
Course Title: Infectious Diseases Elective
Lectures: HIV Therapy
Opportunistic Infections
Dates: 2002 - present
16. Course Number: PHTH 153
Course Title: Pharmaceutical Approaches to ID Therapy
Lectures: Research Endeavors in Antiretroviral Therapy
Dates: 2004 - 2009
17. Course Number: PHCY 450
Course Title: Problems in Pharmacotherapy
Weekly Facilitator
Dates: 2003 - 2016
18. Course Number: DPET 832
Course Title: Introduction to Applied Pharmacogenomics
Lectures: Viral Pharmacogenomics
Dates: 2002 - present
19. Course Number: DPET 810
Course Title: AIDS: Principles, Practices, and Politics
Lectures: Pharmacodynamics of Antiretroviral Therapy
Introduction to HIV Therapy
PK and TDM of Antiretroviral Therapy
Dates: 2003 - 2009
20. Course Number: PHCY 449 (3rd year course)
Course Title: Infectious Diseases Pharmacotherapy
Lectures: Treatment of HIV Infection
Dates: 2002 – present
21. Course Title: Clinical Skills Laboratory
Weekly Lab Instructor
Dates: 2000 - 2001
22. Course Title: Clinical Skills Laboratory
Lectures: Practical Issues in Administering Antibiotics

- Dates: 2000 - 2001
23. Course Title: Women's Health Issues
Lectures: Menstrual Dysfunction
Dates: 1998 - 1999

JOURNAL REVIEWER

1. Journal of Acquired Immunodeficiency Syndrome (January 2004 - present)
2. Drugs (February 2004 - present)
3. Journal of Infectious Diseases (February 2004 - present)
4. Expert Opinion in Pharmacotherapy (April 2004 - present)
5. Clinical Infectious Diseases (May 2004 - present)
6. Antiviral Therapy (January 2006 - present)
7. Journal of Antimicrobial Chemotherapy (January 2006 - present)
8. AIDS Research and Human Retroviruses (January 2007 - present)
9. Future Drugs (January 2007 - present)
10. Pharmacotherapy (September 2008 - present)
11. Journal of Clinical Pharmacology (March 2010-present)

INVITED PRESENTATIONS/CONSULTATIONS

1. *Integrative Medicine*
33rd Annual Pharmacy Practice Seminar
August 24, 2018
Wrightsville Beach, NC
2. *Dietary Supplements: A Practical Approach*
Transforming Wellness: With the Healthcare Professional in Mind
April 27, 2018
Greensboro, NC
3. *Overview of Integrative Medicine*
32nd Annual Pharmacy Practice Seminar
August 26, 2017
Wrightsville Beach, NC
4. *Safe Use of Dietary Supplements and Prescription Medications: Herb-Drug Interactions*
Wake AHEC, New Drugs and Disease Management Strategies
November 18, 2016
Cary, NC
5. *Overview of Integrative Medicine*
UNC/ASHP Grand Rounds
October 11, 2016
Chapel Hill, NC
6. *From Echinacea to Valerian: An Herbal Primer for Wellness Professionals*
41st Annual National Wellness Conference

June 29, 2016

7. *Case Studies in Pharmacological Interactions*
HIV Care in 2016: Clinical Update and Vulnerable Populations
May 2, 2016
Chapel Hill, NC
8. *Integrative Health Approaches to Pain Management*
HIV Care in 2016: Clinical Update and Vulnerable Populations
May 2, 2016
Chapel Hill, NC
9. *HIV and HCV Update*
North Carolina Association of Pharmacists
Raleigh, NC, Nov 2015
10. *Integrative Medicine: A 'Western Perspective'*
75th FIP World Congress of Pharmacy and Pharmaceutical Sciences
Dusseldorf, Germany, Oct 2015
11. *HIV and HCV Update*
Durham-Orange Pharmaceutical Association
Chapel Hill, NC, Sept 2015
12. *HCV Review*
UNC Horizons
Chapel Hill, NC, Apr 2015
13. *HIV and HCV Update*
UNC Eshelman School of Pharmacy Alumni Weekend
Pinehurst, NC, Feb 2015
14. *HIV Update*
15th Annual Anti-infective Workshop
Greensboro, NC, Nov 2014
15. *HIV and HCV Treatment Update*
2014 NCAP Annual Convention
Raleigh, NC, Oct 2014
16. *Update on HIV and HCV*
29th Annual Pharmacy Practice Seminar
Wrightsville Beach, NC, August 2014
17. *HIV Treatment Update*
UNC Project, Tiziwe Center
Lilongwe, Malawi, March 2014
18. *HIV and HCV Update for Pharmacists*
UNC HIV Update, May 2014

19. *HIV Treatment Update*
ASHP and UNC Pharmacy Grand Rounds, March 2014
20. *FDA Mock Advisory Committee Meeting*
Trius Therapeutics
Carlsbad, CA, Jan 2014
21. *HIV For the Non-HIV Specialist*
2nd Annual Mountain Pharmacy Practice Seminar in the Mountains
Asheville, NC, May 2013
22. *HIV Treatment Update*
World AIDS Day, Area L AHEC
Rocky Mount, NC, November 2012
23. *Mitigating the Burden of HIV: The Health-System Pharmacist's Blueprint to Antiretroviral Therapy*
Pharmacists Learning Network
Tampa, FL, November 2012
24. *HIV Treatment Update*
27th Annual Pharmacy Practice Seminar
Wrightsville Beach, NC, Aug 2012
25. *Evaluating Emerging Treatment for Hepatitis C Infection*
Smith Drug Conference
Asheville, NC, July 2012
26. *HIV Update*
Triangle College of Clinical Pharmacy
Chapel Hill, NC, June 2012
27. *Constructing Antiretroviral Regimens to Overcome Imperfect Adherence*
International Association of Physicians in AIDS Care
Miami Beach, FL, June 2012
28. *Management of Patients Diagnosed with HIV: The Pharmacists Role in Care*
Eastern Area Health Education Center
Elizabeth City, NC, March 2012
29. *Issues in the Co-Administration of Antiretrovirals and Direct-acting Antivirals*
2011 Annual Clinical Care Options HIV and HCV Symposium
Washington, DC, June 2011
30. *Antiretroviral Pharmacology Cases*
UNC HIV Care 2011
Chapel Hill, North Carolina, May 2011
31. *Drug Interactions with Antiretroviral Medications and Concomitant Diseases: Treating HIV, Addiction, and Mental Health*

2nd Conference on Dangerous Intersections: Addiction, HIV, and Mental Health in Corrections
Atlantic Beach, North Carolina, May 2010

32. *Drug Interactions Among Antiretrovirals*
UNC HIV Care 2010
Chapel Hill, North Carolina, May 2010
33. *Application of Pharmacogenomics in the Real World: Treatment of HIV*
American College of Clinical Pharmacy
Spring Forum
Charlotte, North Carolina, April 2010
34. *HIV Local Champion Training*
Piedmont HIV Health Care Consortium
Carrboro, NC, Feb 2010
35. *Antiretroviral Medications: Used to Treat HIV Infected Patients*
Janet Reaves Memorial Conference
North Carolina Community Health Care Association
North Carolina AIDS Education and Training Center
Research Triangle Park, North Carolina, Feb 2010
36. *Addressing Antiretroviral Challenges in the Developing World*
UNC World AIDS Day
Chapel Hill, North Carolina, Dec 2009
37. *HIV Medications: Effectively Treating Your Patient*
North Carolina AIDS Education and Training Center
Lumberton, North Carolina, Oct 2009
38. *HIV Medications: Effectively Treating Your Patient*
North Carolina AIDS Education and Training Center
Charlotte, North Carolina, May 2009
39. *HIV Treatment Update*
Wake Med Hospital
Wake AHEC and North Carolina AIDS Education and Training Center
Raleigh, North Carolina, December 2008
40. *HIV Treatment Update*
Wilson Medical Center Continuing Education Symposium
Area L AHEC and North Carolina AIDS Education and Training Center
Wilson, North Carolina, November 2008
41. *HIV Antiretroviral Update*
3rd Annual North Carolina State HIV Prevention Conference
North Carolina AIDS Education and Training Center
New Bern, North Carolina, August 2008
42. *HIV Update*

American Associated of Pharmacy Technicians
Annual Meeting
North Carolina AIDS Education and Training Center
Raleigh, North Carolina, August 2008

43. *Roundtable Discussion-HIV Pharmacology*
HIV Care 2008
UNC Center for AIDS Research
Chapel Hill, North Carolina, May 2008
44. *HIV Update*
North Carolina Eastern Area Health Education Center and
North Carolina AIDS Education and Training Center
Greenville, North Carolina, May 2008
45. *Update on HIV*
North Carolina Association of Pharmacists
Annual Convention, Research Triangle Park, North Carolina, October
2007
46. *Antiretroviral Pharmacology*
UNC School of Medicine ID Fellows
Core Curriculum
Chapel Hill, North Carolina, October 2007
47. *Human Papilloma Disease*
Kappa Epsilon, 46th National Convention
Charlotte, North Carolina, July 2007
48. *Antiretroviral Therapy Update*
The University of Texas Health Center
Tyler, Texas, June 2007
49. *Significant Paper in HIV*
North Carolina Association of Pharmacists
Research Triangle Park, North Carolina, October 2005
50. *Antiretroviral Drug Interaction Update*
Johnson City, Tennessee / Abbott Laboratories, June 2005
51. *Antiretroviral Drug Interaction Update*
East Carolina University / Abbott Laboratories
Greenville, North Carolina, April 2005
52. *Current Choices, Future Options*
Abbott Laboratories
Durham, North Carolina, February 2005
53. *International Issues in Pharmacology of Antiretrovirals*
UNC School of Pharmacy, Division of Pharmacotherapy
Chapel Hill, North Carolina, November 2004

54. *HIV Update*
Southern Regional AHEC, UNC School of Pharmacy
Southern Pines, North Carolina, August 2004
55. *HIV Therapy*
Wake Pharmaceutical Association / Roche Pharmaceuticals
Raleigh, North Carolina, April 2004
56. *Efficacy, Safety, and Pharmacokinetics of An Amprenavir/Saquinavir/Ritonavir
BID Salvage Regimen*
Infectious Diseases Fellows Forum
Naples, Florida, April 2002
57. *Efficacy, Safety, and Pharmacokinetics of An Amprenavir/Saquinavir/Ritonavir
BID Salvage Regimen*
UNC AIDS Clinical Trials Unit, Clinical Research Meeting
Chapel Hill, North Carolina, March 2002
58. *Impact of HIV Genotyping on Choice of Antiretrovirals*
UNC Infectious Diseases Conference
Chapel Hill, North Carolina, September 2001
Southeastern Residency Conference
Athens, Georgia, April 2001
59. *New and Emerging Antifungals*
UNC Hospitals CE Program
Chapel Hill, North Carolina, February 2001
60. *Once Daily Aminoglycosides in Gram Positive Endocarditis*
UNC School of Pharmacy, UNC Hospitals
Chapel Hill, North Carolina, October 2000
61. *Intravenous Line-Related Infections*
UNC School of Pharmacy, UNC Hospitals
Chapel Hill, North Carolina, August, 2000
62. *Pediatric HIV Infections*
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, June 2000
63. *Aminoglycoside Resistant Enterococcal Endocarditis*
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, May 2000
64. *Evaluation of Antimicrobial Use in a Level I Trauma Intensive Care Unit*
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, March 2000
Southeastern Residency Conference
Athens, Georgia, April 2000

65. *Overview of Antibiotics*
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, February 2000

66. *Viral Hepatitis*
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, January 2000